Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study

Table 1 Clinical features of patients receiving rabeprazole plus irsogladine maleate (group I) or rabeprazole plus placebo (group P)

	Group I (n = 49)	Group P (n = 48)	P value
Age (yr), mean ± SD	51.1 ± 16.4	51.1 ± 14.8	0.77
Sex, male/female	13/36	19/29	0.17
BMI (kg/m2)	22.4 ± 4.3	21.8 ± 3.1	0.59
Height (cm)	159 ± 7.3	161.5 ± 8.7	0.24
Weight (kg), mean ± SD	57.1 ± 12.2	56.7 ± 8.6	0.63
NERD grade (N/M)	21/28	20/28	0.91
Hiatal hernia (+/-)	11/38	10/38	0.85
Drinking (+/-)	16/33	20/28	0.36
Smoking (+/-)	2/47	9/39	0.05

NERD: Non-erosive reflux disease; BMI: Body mass index.

Table 2 Clinical features of non-erosive reflux disease Grade N and M

	Grade N (n = 56)	Grade M (n = 41)	P value
Age (yr), mean ± SD	49.8 ± 16.7	53.3 ± 13.7	0.32
Sex, male/female	14/42	18/23	0.05
BMI (kg/m2)	22.5 ± 4.4	21.5 ± 2.6	0.44
Height (cm)	158.6 ± 7.3	162.9 ± 8.3	0.02
Weight (kg)	56.7 ± 12.1	57.2 ± 8.4	0.50
Hiatal hernia (+/-)	7/49	14/27	0.02
Drinking (+/-)	17/39	18/23	0.10
Smoking (+/-)	7/49	8/23	0.30

BMI: Body mass index.